CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Raynaud's phenomenon - Management
Additional information
- There is either evidence of no benefit or insufficient evidence to recommend the use of the following treatments for primary Raynaud's phenomenon:
- Drugs:
- Other peripheral vasodilators, including naftidofuryl oxalate, moxisylyte, buflomedil, and inositol nicotinate.
- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor antagonists.
- Phosphodiesterase inhibitors.
- Prazosin (an alpha receptor blocker).
- Complementary and alternative treatments:
- Thermal biofeedback.
- Chinese acupuncture.
- Evening primrose oil.
- Ginkgo biloba.
- The following treatments are not recommended for use in primary care for secondary Raynaud's phenomenon because of insufficient evidence or lack of feasibility:
- Drugs:
- Naftidofuryl oxalate.
- ACE inhibitors and angiotensin-II receptor antagonists.
- Alpha-receptor blockers.
- Anti-thrombotics/inhibitors of platelet aggregation.
- Glyceryl trinitrate (transdermal).
- Moxisylyte.
- Inositol nicotinate.
- Phosphodiesterase inhibitors.
- Serotonin-reuptake inhibitors.
- Oral prostaglandins.
- Bosentan (on grounds of cost and because it should be used under specialist supervision).
- Complementary and alternative treatments:
- Biofeedback.
- Relaxation therapy.
© NHS Institute for Innovation and Improvement